Oxford Nanopore Technologies PLC announced a ‘landmark’ project with Singapore’s National Precision Medicine programme, which is led by Precision Health Research in Singapore.
The Oxford-based specialist in DNA and RNA sequencing technologies said it will sequence 10,000 genomes aimed at developing a catalogue of structural variants that have shown significance in helping clinician scientists to understand human genetic diversity and diseases.
The company expects the project, which started in mid-2024, to last for about a year. There is no change to its 2024 and medium-term financial guidance.
Chief Executive Officer Gordon Sanghera said: ‘We are excited to collaborate with Singapore’s National Precision Medicine programme to create one of the most extensive and inclusive reference genome datasets globally. This collaboration not only enhances our commitment to precision healthcare but also strategically positions Singapore as a pivotal hub for genomics in the Asia Pacific, fostering significant advancements in medical research and healthcare outcomes.’
Oxford Nanopore shares were down 0.1% to 119.52 pence each on Monday morning in London.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
